摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-bromosalicyl alcohol isopropylidene acetal | 876911-15-8

中文名称
——
中文别名
——
英文名称
3-bromosalicyl alcohol isopropylidene acetal
英文别名
8-Bromo-2,2-dimethyl-4H-benzo[d][1,3]dioxine;8-bromo-2,2-dimethyl-4H-1,3-benzodioxine
3-bromosalicyl alcohol isopropylidene acetal化学式
CAS
876911-15-8
化学式
C10H11BrO2
mdl
——
分子量
243.1
InChiKey
UOHNNAOIKXQJCE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    299.6±40.0 °C(Predicted)
  • 密度:
    1.405±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2932999099

SDS

SDS:5d487a326e134023320138a43427f80f
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Bis-cycloSal-d4T-monophosphates:  Drugs That Deliver Two Molecules of Bioactive Nucleotides
    摘要:
    Bis-cycloSal-d4T-monophosphates have been synthesized as potentially anti-HIV active "dimeric" prodrugs of 2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (d4TMP). These pronucleotides display a mask-drug ratio of 1:2, a novelty in the field of pronucleotides. Both bis-cycloSal-d4TMP 6 and bis-5-methyl-cycloSal-d4TMP 7 showed increased hydrolytic stability as compared to their "monomeric" counterparts and a completely selective hydrolytic release of d4TMP. The hydrolysis pathway was investigated via P-31 NMR spectroscopy. Moreover, due to the steric bulkiness, compound 6 already displayed strongly reduced inhibitor potency toward human butyrylcholinesterase (BChE), while compound 7 turned out to be devoid of any inhibitory activity against BChE. Partial separation of the diastereomeric mixture of 6 revealed strong dependence of the pronucleotides' properties on the stereochemistry at the phosphorus centers. Both 6and 7 showed good activity against HIV-1 and HIV-2 in wild-type CEM cells in vitro. These compounds were significantly more potent than the parent nucleoside d4T 1in HIV-2-infected TK-deficient CEM cells, indicating an efficient TK-bypass.
    DOI:
    10.1021/jm0611713
  • 作为产物:
    描述:
    2-溴苯酚对甲苯磺酸丙酸 、 sodium sulfate 、 苯硼酸 作用下, 以 丙酮甲苯 为溶剂, 反应 90.75h, 生成 3-bromosalicyl alcohol isopropylidene acetal
    参考文献:
    名称:
    带有酯酶可切割位点的第二代cycloSal-d4TMP 前核苷酸——“诱捕”概念
    摘要:
    介绍了 cycloSal-核苷酸方法的扩展。将酶可裂解的酯/酰基基团连接到 cycloSal-d4TMP 三酯上应该允许这些化合物在裂解后被捕获在细胞内。在环Sal环系统的3-或5-位引入酯/酰基基团,并且在CEM细胞提取物的水解研究中观察到关于酯/酰基部分的惊人差异。虽然乙酰基酯和乙酰丙酸酯很容易裂解,但 cycloSal-d4TMP 酸的烷基酯证明对酶促裂解具有抗性。相比之下,AM-、POM- 和 POC-酰基在提取物中迅速裂解,产生 cycloSal-d4TMP 酸。还介绍了化合物对 HIV 的抗病毒活性。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006)
    DOI:
    10.1002/ejoc.200500490
点击查看最新优质反应信息

文献信息

  • HYDROXYLATED CONTRAST ENHANCEMENT AGENTS AND IMAGING METHOD
    申请人:Grimmond Brian James
    公开号:US20110243858A1
    公开(公告)日:2011-10-06
    A method of diagnostic imaging is disclosed comprising administering a medical formulation to a subject, the formulation comprising a contrast enhancement agent having structure I and salts thereof wherein R 1 is independently at each occurrence a hydroxy group, a C 1 -C 3 hydroxyalkyl group, or a C 1 -C 3 alkyl group, and b is 0-4; R 2 -R 7 are independently at each occurrence hydrogen, a C 1 -C 3 hydroxyalkyl group, or a C 1 -C 3 alkyl group, with the proviso that at least one of R 1 -R 7 is a hydroxy group or a C 1 -C 3 hydroxyalkyl group; and wherein Q is one or more charge balancing counterions; and one or more pharmaceutically acceptable carriers and excipients. The subject is subjected to a diagnostic imaging technique such as magnetic resonance imaging. The technique may be used in a variety of diagnostic imaging regimes, such as imaging of circulatory systems, genitourinary systems, hepatobiliary systems, central nervous systems, tumors, and abscesses among others.
    揭示了一种诊断成像方法,包括向受试者注射医用配方,该配方包括具有结构I和其盐的对比增强剂,其中R1在每次出现时独立地是羟基、C1-C3羟基烷基或C1-C3烷基,b为0-4;R2-R7在每次出现时独立地是氢、C1-C3羟基烷基或C1-C3烷基,但至少其中之一是羟基或C1-C3羟基烷基;Q是一个或多个电荷平衡的对离子;以及一个或多个药用载体和赋形剂。受试者接受诊断成像技术,如磁共振成像。该技术可用于各种诊断成像方案,如循环系统、泌尿系统、肝胆系统、中枢神经系统、肿瘤和脓肿等的成像。
  • BIFUNCTIONAL CHELATING AGENTS
    申请人:GENERAL ELECTRIC COMPANY
    公开号:US20140088314A1
    公开(公告)日:2014-03-27
    A chelating agent, a metal-chelate, and a contrast agent are provided, wherein the chelating agent comprises a compound of structure (I) wherein R 1 , R 2 , R 3 , R 8 , R 7 , R′ 7 R′ 1 , R′ 2 , R′ 3 and R 8 ′ are selected from a hydrogen, a protected C 1 -C 3 hydroxyalkyl group, a C 1 -C 3 alkyl group; R 4 and R′ 4 are selected from a hydrogen, a hydroxyl group, a protected hydroxy group, a protected C 1 -C 3 hydroxyalkyl group, a C 1 -C 3 alkyl group; n is an integer between 0 and 4; R 5 and R′ 5 are selected from a hydrogen, a protecting group selected from the group consisting of C 1 -C 30 aliphatic radicals, C 3 -C 30 cycloaliphatic radicals, C 2 -C 30 aromatic radicals; R 9 and R′ 9 are selected form a hydrogen or a protecting group selected from the group consisting of C 1 -C 30 aliphatic radicals, C 3 -C 30 cycloaliphatic radicals, C 2 -C 30 aromatic radicals, m is an integer between 0 and 10; and at least one of R 7 and R′ 7 is acidic group or a protected acidic group.
    提供了一种螯合剂、金属螯合物和对比剂,其中螯合剂包括结构(I)的化合物,其中R1、R2、R3、R8、R7、R′7、R′1、R′2、R′3和R8′从氢、受保护的C1-C3羟基烷基基团、C1-C3烷基基团中选择;R4和R′4从氢、羟基、受保护的羟基、受保护的C1-C3羟基烷基基团、C1-C3烷基基团中选择;n是0到4之间的整数;R5和R′5从氢、选自C1-C30脂肪基、C3-C30环脂肪基、C2-C30芳香基的保护基中选择;R9和R′9从氢或选自C1-C30脂肪基、C3-C30环脂肪基、C2-C30芳香基的保护基中选择;m是0到10之间的整数;并且R7和R′7中的至少一个是酸性基团或受保护的酸性基团。
  • Contrast enhancement agents and method of use thereof
    申请人:General Electric Company
    公开号:US09155804B2
    公开(公告)日:2015-10-13
    A contrast agent composition and a method of diagnostic imaging are provided. The composition comprises a pharmaceutically acceptable carrier and a metal-complex comprising a ligand having structure (XXX): wherein R1, R2, R3, R7, R8, R′1, R′2, R′3, R7′ and R8′ are selected form hydrogen, a protected C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group; R4, R′4 are selected from a hydrogen, a hydroxyl, a protected hydroxyl group, a protected C1-C3 hydroxyalkyl group, a C1-C3 alkyl group; n is an integer between 0 and 4; R5, R′5 are selected from a hydrogen, a protecting group comprising C1-C30 aliphatic radicals, C3-C30 cycloaliphatic radicals, C2-C30 aromatic radicals, m is an integer between 1 and 10; at least one of R7 and R′7 is acidic groups or protected acidic groups; Y comprises a protein or peptide moiety, a particle, a micelle, a liposome, an organic molecule, oligomer, polymer or a hydrophilic moiety.
    提供了一种对比剂组合物和一种诊断成像方法。该组合物包括一种药用载体和一种金属配合物,其包括具有结构(XXX)的配体:其中R1、R2、R3、R7、R8、R′1、R′2、R′3、R7′和R8′从氢、受保护的C1-C3羟基烷基或C1-C3烷基中选择;R4、R′4从氢、羟基、受保护的羟基基团、受保护的C1-C3羟基烷基或C1-C3烷基中选择;n是0到4之间的整数;R5、R′5从氢、包含C1-C30脂肪基、C3-C30环脂基、C2-C30芳香基的保护基中选择;m是1到10之间的整数;R7和R′7中的至少一个是酸性基团或受保护的酸性基团;Y包括蛋白质或肽基团、粒子、胶束、脂质体、有机分子、寡聚体、聚合物或亲水基团。
  • CONTRAST ENHANCEMENT AGENTS AND METHOD OF USE THEREOF
    申请人:GENERAL ELECTRIC COMPANY
    公开号:US20140086846A1
    公开(公告)日:2014-03-27
    A contrast agent composition and a method of diagnostic imaging are provided. The composition comprises a pharmaceutically acceptable carrier and a metal-complex comprising a ligand having structure (XXX): wherein R 1 , R 2 , R 3 , R 7 , R 8 , R′ 1 , R′ 2 , R′ 3 , R 7 ′ and R 8 ′ are selected form hydrogen, a protected C 1 -C 3 hydroxyalkyl group, or a C 1 -C 3 alkyl group; R 4 , R′ 4 are selected from a hydrogen, a hydroxyl, a protected hydroxyl group, a protected C 1 -C 3 hydroxyalkyl group, a C 1 -C 3 alkyl group; n is an integer between 0 and 4; R 5 , R′ 5 are selected from a hydrogen, a protecting group comprising C 1 -C 30 aliphatic radicals, C 3 -C 30 cycloaliphatic radicals, C 2 -C 30 aromatic radicals, m is an integer between 1 and 10; at least one of R 7 and R′ 7 is acidic groups or protected acidic groups; Y comprises a protein or peptide moiety, a particle, a micelle, a liposome, an organic molecule, oligomer, polymer or a hydrophilic moiety.
    提供了一种对比剂组合物和诊断成像方法。该组合物包括一种药用载体和一种金属配合物,其包括具有结构(XXX)的配体:其中R1、R2、R3、R7、R8、R′1、R′2、R′3、R7′和R8′从氢、受保护的C1-C3羟基烷基或C1-C3烷基中选择;R4、R′4从氢、羟基、受保护的羟基烷基、受保护的C1-C3羟基烷基或C1-C3烷基中选择;n是0到4之间的整数;R5、R′5从氢、包含C1-C30脂肪基、C3-C30环烷基、C2-C30芳香基的保护基中选择;m是1到10之间的整数;R7和R′7中至少有一个是酸性基团或受保护的酸性基团;Y包括蛋白质或肽基团、粒子、胶束、脂质体、有机分子、寡聚体、聚合物或亲水基团。
  • NOVEL <i>CYCLOSAL</i> NUCLEOTIDES WITH REDUCED INHIBITORY POTENCY TOWARD HUMAN BUTYRYLCHOLINESTERASE
    作者:C. Ducho、S. Jessel、N. Gisch、J. Balzarini、C. Meier
    DOI:10.1081/ncn-200061791
    日期:2005.4.1
    Two novel cycloSal-d4T monophosphates (d4TMPs) with increased steric demand have been synthesized via a new synthetic route. While 3-cyclohexyl-cycloSal d4TMP did not show a significantly reduced inhibitory potency toward human butrylylcholinesterase, the opposite was the case for the second novel pronucleotide, bi-(cycloSal-d4TMP).
查看更多

同类化合物

顺式-6-氯-4-甲基-4-苯基-4H-1,3-苯并二氧杂环己-2-羧酸 阿莫齐特 苯并二氧六环-6-甲酸甲酯 苯并二氧六环-6-甲酰胺 苯并二氧六环-5-甲酸甲酯 苯并二氧六环-5-甲酰胺 苯并二氧六环-2-磺酰氯 苯并-1,4-二氧六环-6-硼酸 艾泽罗西 胍苯克生 胍美柳 胍生 羧基-6-苯并(4H)二恶英-1,3 美商陆酚A 维兰特罗杂质4 盐酸艾美洛沙 盐酸哌罗克生 盐酸[(7-溴-2,3-二氢-1,4-苯并二恶英-6-基)甲基]肼 甲基氨基甲酸1,4-苯并二恶烷-5-基酯 甲基8-甲基-2,3-二氢-1,4-苯并二氧杂环己烷-6-羧酸酯 甲基7-甲基-2,3-二氢-1,4-苯并二氧杂环己烷-5-羧酸酯 甲基4-[(1E)-3-乙基-3-(羟甲基)三氮杂-1-烯-1-基]苯酸酯 甲基-[2-[(7-丙-2-烯基-2,3-二氢-1,4-苯并二氧杂环己-8-基)氧基]乙基]氯化铵 甲基(2S,4R)-6-氯-4-甲基-4-(2-噻吩基)-4H-1,3-苯并二氧杂环己烷-2-羧酸酯 溴(2,3-二氢-1,4-苯并二氧杂环己-6-基)镁 沙丁胺醇缩丙酮 异戊苯恶烷 度莫辛 布他莫生 安必罗山 地奥地洛 哌扑罗生 咪洛克生 咪唑克生盐酸盐 吡啶-3-磺酰氯盐酸盐 叔丁基 (2,3-二氢苯并[b][1,4]二噁英-6-基)氨基甲酸酯 反式-2,3-二氢-N-((4-(2-苯氧基乙基)-1-哌嗪基)甲基)-1,4-苯并二氧六环-2-甲酰胺 双恶哌嗪 冰达卡醇 依利格鲁司特中间体5 依利格鲁司特 亚达唑散 二氨基亚甲基-(2,3-二氢-1,4-苯并二氧杂环己-2-基甲基)铵硫酸盐 二-(叔丁基)2-(2,2-二甲基-4H-1,3-苯并二恶英-6-基)-2-氧代乙基亚氨基二碳酸 二(吡咯烷甲基)-4-羟基苯基乙酸1,4-苯并二噁烷基-2-甲基酯 乙基2,3-二氢-1,4-苯并二氧杂环己-6-基(氧代)乙酸酯 三氟甲烷磺酸7-甲氧基-2,2-二甲基-4-氧代-4H-1,3-苯并二氧杂环己-5-基酯 alpha-[[N-(2-甲氧基乙基)甲基氨基]甲基]-1,4-苯并二恶烷-2-甲醇 alpha-[[(4-甲氧基丁基)甲基氨基]甲基]-1,4-苯并二恶烷-2-甲醇 alpha-[[(4-甲氧基丁基)氨基]甲基]-alpha-甲基-1,4-苯并二恶烷-2-甲醇